Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time[1][2][3].
Molecular Weight:
(78 kDa)
Purity:
95.00
CAS Number:
[1450981-87-9]
Target:
TNF Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
